Take Me Out To the Public Markets: Device VCs Swing Big Bats
This article was originally published in Start Up
Medical device investors see the potential for significant returns from the recent spate of initial public offerings, and they're tending to outperform their biopharmaceutical counterparts.
You may also be interested in...
The difficulties on Wall Street are washing down to the private market causing medical device VCs to reconsider investment strategies and exiting routes.
Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.